Literature DB >> 6571717

Differentiation patterns in the blastic phase of chronic myeloid leukemia.

J D Griffin, R F Todd, J Ritz, L M Nadler, G P Canellos, D Rosenthal, M Gallivan, R P Beveridge, H Weinstein, D Karp, S F Schlossman.   

Abstract

The surface antigen phenotype of 30 patients with the blast phase of chronic myeloid leukemia (CML) was determined using a panel of monoclonal antibodies recognizing differentiation antigens of normal myeloid, erythroid, megakaryocyte, and lymphoid cells. Ten patients' cells expressed a phenotype corresponding to an immature myeloid cell and were felt to have "myeloid" blast crisis. None of these myeloid leukemias were TdT+ or responded to vincristine (V) and prednisone (P). Eleven patients expressed a phenotype similar to acute lymphoblastic leukemia cells and probably reflect maturation to an early B lymphocyte. All of these "lymphoid" leukemias were TdT+, and 67% of evaluable patients had a complete response to V and P. One leukemia had the phenotype of an erythroleukemia, one patient's cells expressed the phenotype of megakaryoblastic leukemia, and one leukemia had populations of both myeloid and lymphoid blasts. Six leukemias did not express surface markers characteristic of any lineage and were termed "undifferentiated." This group was heterogeneous with respect to TdT expression, but no patient had a complete response to V and P. Determination of surface antigen phenotype in CML blast crisis thus provides clinically useful information for the structuring of treatment protocols.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6571717

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Immunophenotypic analysis of various blastic crises in chronic myeloid leukemia: correlations between CD7 expression and response to chemotherapy.

Authors:  Yuko Hirose; Yasufumi Masaki; Kumiko Shimoyama; Toshihiro Fukushima; Hiroshi Kawabata; Noriyoshi Ogawa; Yuji Wano; Susumu Sugai
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

2.  Development of acute leukaemia after idiopathic myelofibrosis.

Authors:  J M Hernández; J F San Miguel; M González; A Orfao; M C Cañizo; C Bascones; J Hernández; A López Borrasca
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

3.  Chronic myelogenous leukemia--recent advances in treatment and pathogenesis.

Authors:  A B Deisseroth; S Purohit; A R Lopez
Journal:  West J Med       Date:  1986-03

4.  BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.

Authors:  Masahiro Tokunaga; Sachiko Ezoe; Hirokazu Tanaka; Yusuke Satoh; Kentaro Fukushima; Keiko Matsui; Masaru Shibata; Akira Tanimura; Kenji Oritani; Itaru Matsumura; Yuzuru Kanakura
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

5.  Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate.

Authors:  Vasantha Thavaraj; Rachna Seth
Journal:  World J Pediatr       Date:  2008-05       Impact factor: 2.764

6.  In vivo differentiation of blast-phase chronic granulocytic leukemia. Expression of c-myc and c-abl protooncogenes.

Authors:  C A Koller; V W Campbell; D A Polansky; A Mulhern; D M Miller
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

Review 7.  Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.

Authors:  Christian Sillaber; Matthias Mayerhofer; Hermine Agis; Verena Sagaster; Christine Mannhalter; Wolfgang R Sperr; Klaus Geissler; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

8.  Remission-induction of acute lymphoblastic transformation of chronic myeloid leukaemia, followed by long-term maintenance therapy.

Authors:  T de Witte; B de Pauw; C Haanen
Journal:  Blut       Date:  1986-04

9.  Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia.

Authors:  Sonya Haslam
Journal:  Core Evid       Date:  2005-03-31

Review 10.  Treatment selection after imatinib resistance in chronic myeloid leukemia.

Authors:  Elias Jabbour; Jorge Cortes; Hagop Kantarjian
Journal:  Target Oncol       Date:  2009-01-30       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.